Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $162.1 million for Q1 2026.

• On a quarterly basis, Revenue rose 106.87% year-over-year to $162.1 million in Q1 2026; TTM through Mar 2026 was $535.1 million, a 128.99% increase from a year earlier, with the FY2025 full-year figure at $451.4 million, up 146.71% from the prior year.
• Revenue climbed to $162.1 million in Q1 2026 per TARS's latest filing, from $151.7 million in the prior quarter.
• Across five years, Revenue topped out at $162.1 million in Q1 2026 and bottomed at $539000.0 in Q1 2022.
• The 5-year median for Revenue is $40.8 million (2024), against an average of $56.0 million.
• Biggest YoY gain for Revenue was 2858.58% in 2022; the steepest drop was 98.39% in 2022.
• Year by year, Revenue stood at $10.0 million in 2022, then jumped by 30.76% to $13.1 million in 2023, then jumped by 407.86% to $66.4 million in 2024, then surged by 128.39% to $151.7 million in 2025, then grew by 6.85% to $162.1 million in 2026.
• Per Business Quant, the three latest TARS Revenue figures stand at $162.1 million (Q1 2026), $151.7 million (Q4 2025), and $118.7 million (Q3 2025).